Literature DB >> 30157096

Validation of a Nomogram for Achieving Target Trough Concentration of Vancomycin: Accuracy in Patients With Augmented Renal Function.

Hidetoshi Ishii1,2, Keita Hirai1,3, Kyohei Sugiyama2, Eiji Nakatani4,5, Midori Kimura2, Kunihiko Itoh1,3.   

Abstract

BACKGROUND: Adjustment of initial vancomycin (VCM) dosage has been recommended on the basis of the renal function nomogram in therapeutic drug monitoring guidelines in Japan. However, this nomogram has not been clinically validated, and few studies have focused on its usefulness in patients with risk of augmented renal function. Therefore, this study aimed to evaluate the validity of the VCM nomogram and the association between patient conditions related to augmented renal function and its accuracy.
METHODS: In this retrospective study, we screened data of 398 patients who received VCM and had estimated glomerular filtration rates ≥30 mL·min·1.73 m. Patients who met nomogram dosing criteria were categorized into a nomogram group, and the associations of age, renal function, and individual conditions such as febrile neutropenia, solid tumor, blood cancer, and brain injury with subtherapeutic concentrations (<10.0 mcg/mL) of VCM were evaluated.
RESULTS: In total, 177 patients were categorized into the nomogram group, and 83 (47%), 81 (46%), and 13 patients (7%) had VCM trough concentrations of 10-20, <10, and >20 mcg/mL, respectively. Age <50 years was only significantly associated with subtherapeutic trough concentrations. Specific conditions of patients such as febrile neutropenia, solid tumor, and blood cancer were associated with elevated VCM clearance; however, there was no decline in trough VCM concentrations regardless of the presence of the specific conditions.
CONCLUSIONS: The Japanese VCM dosing nomogram was effective in minimizing the number of instances of supratherapeutic VCM serum concentrations; however, it lacked accuracy in achieving target trough concentrations. The accuracy of the nomogram could be enhanced by categorizing patients according to age. Nevertheless, this study provides novel evidence of the usefulness of this nomogram in avoiding subtherapeutic concentrations of VCM in patients with risk factors for augmented renal clearance.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30157096     DOI: 10.1097/FTD.0000000000000562

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  5 in total

Review 1.  Drug Dosing in Critically Ill Adult Patients with Augmented Renal Clearance.

Authors:  Fatma Hefny; Sukhvir Sambhi; Cassidy Morris; Janice Y Kung; Anna Stuart; Sherif Hanafy Mahmoud
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2022-06-28       Impact factor: 2.569

2.  A higher dose of vancomycin is needed in critically ill patients with augmented renal clearance.

Authors:  Juan He; Zhi-Tao Yang; Xian Qian; Bing Zhao; En-Qiang Mao; Er-Zhen Chen; Xiao-Lan Bian
Journal:  Transl Androl Urol       Date:  2020-10

3.  Development of a decision flowchart to identify the patients need high-dose vancomycin in early phase of treatment.

Authors:  Ryo Yamaguchi; Hiroko Kani; Takehito Yamamoto; Takehiro Tanaka; Hiroshi Suzuki
Journal:  J Pharm Health Care Sci       Date:  2022-01-04

Review 4.  Prevalence and Risk Factors of Augmented Renal Clearance: A Systematic Review and Meta-Analysis.

Authors:  Fatma Hefny; Anna Stuart; Janice Y Kung; Sherif Hanafy Mahmoud
Journal:  Pharmaceutics       Date:  2022-02-19       Impact factor: 6.321

Review 5.  Clinical Practice Guidelines for Therapeutic Drug Monitoring of Vancomycin in the Framework of Model-Informed Precision Dosing: A Consensus Review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.

Authors:  Kazuaki Matsumoto; Kazutaka Oda; Kensuke Shoji; Yuki Hanai; Yoshiko Takahashi; Satoshi Fujii; Yukihiro Hamada; Toshimi Kimura; Toshihiko Mayumi; Takashi Ueda; Kazuhiko Nakajima; Yoshio Takesue
Journal:  Pharmaceutics       Date:  2022-02-23       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.